SPX 101

Drug Profile

SPX 101

Alternative Names: SPX-101

Latest Information Update: 28 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Spyryx Biosciences
  • Class Peptides
  • Mechanism of Action Epithelial sodium channel-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 20 Jun 2017 Efficacy data from a phase I trial in Cystic fibrosis released by Spyryx Biosciences
  • 31 May 2017 Phase-Ib clinical trials in Cystic fibrosis in Canada (Inhalation) (NCT03056989)
  • 05 Apr 2017 Spyryx Biosciences plans the HOPE-1 phase II trial for Cystic fibrosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top